Product Description: Besifloxacin (Hydrochloride) (Standard) is a fourth generation fluoroquinolone antibiotic. Besifloxacin Hydrochloride (Standard) is a DNA gyrase and topoisomerase IV inhibitor. Besifloxacin Hydrochloride (Standard) has broad-spectrum antibacterial activity, it is effective against Gram-negative and Gram-positive aerobic and anaerobic strains and reduces the incidence of drug resistance. Besifloxacin Hydrochloride (Standard) has anti-inflammatory activity. Besifloxacin Hydrochloride (Standard) can be used in bacterial conjunctivitis research[1][2][3][4].
Formula: C19H22Cl2FN3O3
References: [1]Wang Z, Wang S, Zhu F, Chen Z, Yu L, Zeng S.
Determination of enantiomeric impurity in besifloxacin hydrochloride by chiral high-performance liquid chromatography with precolumn derivatization.
Chirality. 2012 Jul;24(7):526-31. doi: 10.1002/chir.22042./[2]Hussar DA.
New drugs: golimumab, besifloxacin hydrochloride, and artemether/lumefantrine.
J Am Pharm Assoc (2003). 2009 Jul-Aug;49(4):570-4./[3]Nafziger AN, Bertino JS Jr.
Besifloxacin ophthalmic suspension for bacterial conjunctivitis.
Drugs Today (Barc). 2009 Aug;45(8):577-88./[4]Proksch JW, Ward KW.
Ocular pharmacokinetics/pharmacodynamics of besifloxacin, moxifloxacin, and gatifloxacin following topical administration to pigmented rabbits.
J Ocul Pharmacol Ther. 2010 Oct;26(5):449-58./[5]Comstock TL, Paterno MR, Usner DW, Pichichero ME.
Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials.
Paediatr Drugs. 2010 Apr 1;12(2):105-12. doi: 10.2165/11534380-000000000-00000./[6]Zhang JZ, et al. Besifloxacin, a novel fluoroquinolone antimicrobial agent, exhibits potent inhibition of pro-inflammatory cytokines in human THP-1 monocytes. J Antimicrob Chemother. 2008 Jan;61(1):111-6./[7]Sanfilippo CM, et al. Topoisomerase mutations that are associated with high-level resistance to earlier fluoroquinolones in Staphylococcus aureus have less effect on the antibacterial activity of besifloxacin. Chemotherapy. 2011;57(5):363-71./[8]Haas W, et al. Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. Antimicrob Agents Chemother. 2009 Aug;53(8):3552-60./[9]Sanders ME, et al. Efficacy of besifloxacin in an early treatment model of methicillin-resistant Staphylococcus aureus keratitis. J Ocul Pharmacol Ther. 2010 Apr;26(2):193-8.
CAS Number: 405165-61-9
Molecular Weight: 430.30
Research Area: Infection
Target: Antibiotic;Bacterial;DNA/RNA Synthesis;Reference Standards;Topoisomerase
English
Deutsch
